Overview

Comparative Study of Different Doses of Mg as a Protective Agent in Nephrotoxicity in Patients With H and N Cancer

Status:
Enrolling by invitation

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

The goal of this [ type of study: intervential study is to compare between different doses of magnesium to prevent cisplatin induced nephrotoxicity.] In 75 participant population with head and neck cancer recieved cisplatin it aims to answer are: • • optimal doses of magnesium as 3 groups each group take 1gm of magnesium then second group take 2gm of magnesium and finally third group take 3gm of magnesium Researchers will compare [ 3 groups ] to see if [ magnesium has effects in prevention cisplatin nephrotoxicity].

Phase:

Phase 2

Details

Lead Sponsor:

Tanta University

Treatments:

Cisplatin